Aptevo Therapeutics Inc. (APVO) - 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on May 22, 2025, by Aptevo Therapeutics Inc., a Delaware corporation headquartered in Seattle, Washington. The filing addresses critical corporate governance and capital structure events, specifically a Nasdaq delisting notice and a prospective reverse stock split.
Key Financial Metrics
- Stockholders' Equity: The Company reported a stockholders' deficit of $1,473,000 as of March 31, 2025.
- Capital Raised (ATM Program): As of May 22, 2025, the Company had issued and sold 7,989,040 shares under its At The Market (ATM) Offering Agreement, generating aggregate gross proceeds of $3,349,104.
- Remaining ATM Capacity: A new prospectus supplement was filed to offer up to $3,015,515 in additional shares under the existing Sales Agreement.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels for the current period.
Material Changes and Events
- Nasdaq Non-Compliance Notice: On May 22, 2025, Nasdaq notified the Company of non-compliance with Listing Rule 5550(b)(1) due to the stockholders' deficit falling below the required $2,500,000 minimum. The stock continues to trade pending a compliance plan.
- Reverse Stock Split: The Company announced a prospective 1-for-20 reverse stock split, expected to become effective on May 23, 2025, at 5:01 p.m. Eastern Time. Trading on a split-adjusted basis is expected to commence on May 27, 2025.
- ATM Program Update: The Company filed a prospectus supplement to continue its ATM offering, having already raised over $3.3 million under the program.
Outlook, Risks, and Management Commentary
- Compliance Timeline: The Company has 45 calendar days (until July 7, 2025) to submit a plan to regain compliance with Nasdaq equity requirements. If accepted, it may have up to 180 days (until November 18, 2025) to achieve compliance.
- Delisting Risk: There is no assurance that the compliance plan will be accepted or that the Company will regain compliance. Failure to do so could result in delisting, though the Company retains the right to appeal to an independent panel.
- Management Action: Management is evaluating options to resolve the equity deficiency and intends to submit a compliance plan by the deadline.
Investor Verification Checklist
- Verify the effectiveness of the 1-for-20 reverse stock split and the adjusted share count.
- Monitor the submission and acceptance of the Nasdaq compliance plan by July 7, 2025.
- Track the execution of the remaining $3,015,515 capacity under the ATM offering program.
- Review the Company's next quarterly report for updated stockholders' equity and cash position.